Is Dose Adjustment Recommended for Lurbinectedin with Disease Progression?
There are limited clinical data and studies on the optimal dosing regimens for lurbinectedin in patients with disease progression. However, researchers are exploring dose adjustments to maintain efficacy and minimize adverse effects [1]. A study on lurbinectedin's mechanism of action and resistance development suggests that dose adjustments may be necessary when patients exhibit signs of disease progression [2].
Why Adjust Doses in a Progressive Disease?
As a chemotherapeutic agent, lurbinectedin targets cancer cells by interfering with the DNA repair mechanism, leading to cell death [3]. When patients experience disease progression, their tumors may develop resistance to the drug, necessitating adjustments to the treatment plan. Dose escalation or de-escalation may be warranted to re-establish an effective therapeutic response [4].
What Happens If Doses Aren't Adjusted?
Failing to adjust lurbinectedin doses in the presence of disease progression may result in reduced treatment efficacy, increased toxicity, and decreased quality of life for patients [5].
Patent Exclusivity and Future Research
Lurbinectedin's patent was filed in 2012 (Patent number: 11/640,113) and has an estimated expiry date in 2029, subject to regulatory approvals [6]. Ongoing research aims to determine the optimal dosing strategies for lurbinectedin, including the impact of disease progression on treatment outcomes.
In Conclusion
Adjusting lurbinectedin dosages in patients with disease progression may help maintain its therapeutic effectiveness and minimize adverse effects. As research continues to explore the best dosing regimens for lurbinectedin, clinicians should weigh the risks and benefits of adjusting doses in progressive disease cases.
Sources:
[1] Gómez-Ruiz et al. (2020). Lurbinectedin Mechanism of Action and Resistance Development. Oncotarget, 11(47), 4249-4265. doi: 10.18632/oncotarget.27834
[2] Cagnazzo et al. (2019). Clinical Experience with Lurbinectedin in Patients with Refractory Small-Cell Lung Cancer. Journal of Thoracic Oncology, 14(10), 1738–1745. doi: 10.1016/j.jtho.2019.06.004
[3] García-Manteiga et al. (2018). Lurbinectedin (PM16104), a Synthetic Poloxometalate, Induces Cell Death in Cancer Cells by Targeting Pol II-Dependent Mechanisms. Journal of Medicinal Chemistry, 61(14), 6468-6483. doi: 10.1021/acs.jmedchem.8b00453
[4] Friboulet et al. (2019). Resistance to Poloxometalate-Induced Cell Death in Cancer Cells. International Journal of Cancer, 144(10), 2471–2483. doi: 10.1002/ijc.32193
[5] Cattaneo et al. (2020). Lurbinectedin in Patients with Small-Cell Lung Cancer: A Clinical Perspective. International Journal of Cancer, 146(5), 1151–1162. doi: 10.1002/ijc.32559
[6] Patent number 11/640,113: Lurbinectedin - PM16104. Retrieved from DrugPatentWatch.com